小细胞肺癌的耐药机制：与DNA相关、与RNA相关、与凋亡相关、药物蓄积及代谢过程。
Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure.
作者信息
Chen Peixin, Kuang Peng, Wang Lei, Li Wei, Chen Bin, Liu Yu, Wang Hao, Zhao Sha, Ye Lingyun, Yu Feng, He Yayi, Zhou Caicun
机构信息
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Department of Medical School, Tongji University, Shanghai, China.
出版信息
Transl Lung Cancer Res. 2020 Jun;9(3):768-786. doi: 10.21037/tlcr-19-547.
Abstract
Small-cell lung cancer (SCLC), the highest malignant cancer amongst different types of lung cancer, has the feature of lower differentiation, rapid growth, and poor survival rate. Despite the dramatically initial sensitivity of SCLC to various types of treatment methods, including chemotherapy, radiotherapy and immunotherapy, the emergence of drugs-resistance is still a grandly clinical challenge. Therefore, in order to improve the prognosis and develop new therapeutic approaches, having a better understanding of the complex mechanisms of resistance in SCLC is of great clinical significance. This review summarized recent advances in understanding of multiple mechanisms which are involved in the resistance during SCLC treatment, including DNA-related process, RNA-related process, apoptosis-related mechanism, and the process of drug accumulation and metabolism.
摘要
小细胞肺癌（SCLC）是不同类型肺癌中恶性程度最高的癌症，具有分化程度低、生长迅速和生存率低的特点。尽管SCLC对包括化疗、放疗和免疫治疗在内的各种治疗方法最初具有显著的敏感性，但耐药性的出现仍然是一个重大的临床挑战。因此，为了改善预后并开发新的治疗方法，更好地了解SCLC耐药的复杂机制具有重要的临床意义。本综述总结了近年来对SCLC治疗过程中耐药相关多种机制的理解进展，包括与DNA相关的过程、与RNA相关的过程、凋亡相关机制以及药物积累和代谢过程。
相似文献
1
Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure.小细胞肺癌的耐药机制：与DNA相关、与RNA相关、与凋亡相关、药物蓄积及代谢过程。
Transl Lung Cancer Res. 2020 Jun;9(3):768-786. doi: 10.21037/tlcr-19-547.
2
Chemotherapy Resistance Molecular Mechanism in Small Cell Lung Cancer.小细胞肺癌化疗耐药的分子机制。
Curr Mol Med. 2019;19(3):157-163. doi: 10.2174/1566524019666190226104909.
3
Targeted drugs in small-cell lung cancer.小细胞肺癌的靶向药物。
Transl Lung Cancer Res. 2016 Feb;5(1):51-70. doi: 10.3978/j.issn.2218-6751.2016.01.12.
4
Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.HOXA1 基因下调受 miR-100 调控影响小细胞肺癌细胞的存活和化疗耐药性。
Eur J Cancer. 2014 May;50(8):1541-54. doi: 10.1016/j.ejca.2014.01.024. Epub 2014 Feb 19.
5
[Role of SPHK1 regulates multi-drug resistance of small cell lung cancer
and its clinical significance].[鞘氨醇激酶1调节小细胞肺癌多药耐药性的作用及其临床意义]
Zhongguo Fei Ai Za Zhi. 2014 Nov;17(11):769-77. doi: 10.3779/j.issn.1009-3419.2014.11.01.
6
Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs.基于小细胞肺癌细胞的传感器研究及其在抗癌药物化疗效果快速评估中的应用。
Biosens Bioelectron. 2017 Nov 15;97:184-195. doi: 10.1016/j.bios.2017.05.050. Epub 2017 May 31.
7
[Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].[小细胞肺癌患者来源的异种移植动物模型及耐药模型的建立]
Zhongguo Fei Ai Za Zhi. 2019 Jan 20;22(1):6-14. doi: 10.3779/j.issn.1009-3419.2019.01.03.
8
A new hope: the immunotherapy in small cell lung cancer.新希望：免疫疗法在小细胞肺癌中的应用。
Neoplasma. 2016;63(3):342-50. doi: 10.4149/302_151001N511.
9
Biological heterogeneity of small cell lung cancer.小细胞肺癌的生物学异质性。
Semin Oncol. 1985 Sep;12(3):289-303.
10
Therapeutic advances in small cell lung cancer.小细胞肺癌的治疗进展
Expert Opin Investig Drugs. 2000 Mar;9(3):565-79. doi: 10.1517/13543784.9.3.565.
引用本文的文献
1
LncRNA LINC01123-mediated impaired fracture healing through miR-134-5p/XIAP axis.长链非编码RNA LINC01123通过miR-134-5p/XIAP轴介导骨折愈合受损。
J Orthop Surg Res. 2025 Aug 22;20(1):790. doi: 10.1186/s13018-025-06167-3.
2
Epothilone B from Aspergillus fumigatus with a strong antiproliferative and anti-tubulin polymerizing activities; apoptosis, and cell cycle analyses.来自烟曲霉的埃坡霉素B具有强大的抗增殖和抗微管蛋白聚合活性；凋亡及细胞周期分析。
BMC Microbiol. 2025 Jun 26;25(1):367. doi: 10.1186/s12866-025-04086-1.
3
Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies.依托泊苷作为肺癌的关键治疗药物：作用机制、疗效及新策略
Int J Mol Sci. 2025 Jan 18;26(2):796. doi: 10.3390/ijms26020796.
4
Bioprocessing of Epothilone B from Aspergillus fumigatus under solid state fermentation: Antiproliferative activity, tubulin polymerization and cell cycle analysis.固态发酵烟曲霉生产埃博霉素 B 的生物转化：抗增殖活性、微管蛋白聚合和细胞周期分析。
BMC Microbiol. 2024 Jan 30;24(1):43. doi: 10.1186/s12866-024-03184-w.
5
CD209 signaling pathway as a biomarker for cisplatin chemotherapy response in small cell lung cancer.CD209信号通路作为小细胞肺癌顺铂化疗反应的生物标志物
Genes Dis. 2023 Jul 16;11(3):101038. doi: 10.1016/j.gendis.2023.06.011. eCollection 2024 May.
6
Simplified Synthesis of Renieramycin T Derivatives to Target Cancer Stem Cells via β-Catenin Proteasomal Degradation in Human Lung Cancer.通过β-连环蛋白蛋白酶体降解靶向人肺癌中的癌症干细胞简化雷尼尔霉素 T 衍生物的合成。
Mar Drugs. 2023 Nov 30;21(12):627. doi: 10.3390/md21120627.
7
ING5 overexpression upregulates miR-34c-5p/Snail1 to inhibit EMT and invasion of lung cancer cells.ING5 过表达上调 miR-34c-5p/Snail1 抑制肺癌细胞 EMT 和侵袭。
Acta Biochim Biophys Sin (Shanghai). 2023 May 30;55(5):809-817. doi: 10.3724/abbs.2023074.
8
Anticancer Activity of Region B Capsaicin Analogs.区域 B 辣椒素类似物的抗癌活性。
J Med Chem. 2023 Apr 13;66(7):4294-4323. doi: 10.1021/acs.jmedchem.2c01594. Epub 2023 Mar 31.
9
Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates.嵌合抗原受体T细胞对表达癌胚抗原相关细胞黏附分子5（CEACAM5）且对抗体-药物偶联物耐药的非小细胞肺癌细胞有效。
Front Oncol. 2023 Feb 27;13:1124039. doi: 10.3389/fonc.2023.1124039. eCollection 2023.
10
Excellent survival of pathological N0 small cell lung cancer patients following surgery.病理 N0 期小细胞肺癌患者手术后的极佳生存。
Eur J Med Res. 2023 Feb 21;28(1):91. doi: 10.1186/s40001-023-01044-3.
本文引用的文献
1
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗既往治疗的晚期神经内分泌肿瘤的疗效和安全性：来自 II 期 KEYNOTE-158 研究的结果。
Clin Cancer Res. 2020 May 1;26(9):2124-2130. doi: 10.1158/1078-0432.CCR-19-3014. Epub 2020 Jan 24.
2
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
3
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.RRx-001 联合铂类双药与铂类单药三线治疗小细胞肺癌的 REPLATINUM Ⅲ 期随机研究。
Future Oncol. 2019 Oct;15(30):3427-3433. doi: 10.2217/fon-2019-0317. Epub 2019 Sep 11.
4
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.在 DLL3 表达、复发/难治性小细胞肺癌的三线及以上患者中，罗瓦匹妥珠单抗特西利单抗的疗效和安全性：来自 II 期 TRINITY 研究的结果。
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966. doi: 10.1158/1078-0432.CCR-19-1133. Epub 2019 Sep 10.
5
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.在接受一线化疗的小细胞肺癌患者中，用 CDK4/6 抑制剂替拉西利进行骨髓保护：一项 Ib 期/随机 II 期试验。
Ann Oncol. 2019 Oct 1;30(10):1613-1621. doi: 10.1093/annonc/mdz278.
6
Epigenetics of lung cancer: a translational perspective.肺癌的表观遗传学：转化研究视角。
Cell Oncol (Dordr). 2019 Dec;42(6):739-756. doi: 10.1007/s13402-019-00465-9. Epub 2019 Aug 8.
7
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.RRx-001 联合铂类药物加依托泊苷治疗既往治疗的小细胞肺癌患者。
Br J Cancer. 2019 Jul;121(3):211-217. doi: 10.1038/s41416-019-0504-8. Epub 2019 Jun 24.
8
MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.miR-7-5p 下调 PARP1 影响小细胞肺癌中 DNA 同源重组修复和多柔比星耐药性。
BMC Cancer. 2019 Jun 18;19(1):602. doi: 10.1186/s12885-019-5798-7.
9
Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.Notch 通路在小细胞肺癌中的作用：从临床前证据到治疗挑战。
Cell Oncol (Dordr). 2019 Jun;42(3):261-273. doi: 10.1007/s13402-019-00441-3. Epub 2019 Apr 9.
10
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
Zotero 插件